Category: Press Releases

Publication relating to transparency notifications

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification

‫31واں چین یانگلنگ ایگریکلچر ہائی ٹیک فیئر 25 اکتوبر سے شروع ہوگا

یانگلنگ، چین، 25 اکتوبر،2024/ژنہوا-ایشیا نیٹ — 31واں پانچ روزہ چین یانگلنگ ایگریکلچر ہائی ٹیک میلہ مغربی چین کے صوبہ شانگسی کے زرعی سائنس و ٹیکنالوجی مرکز، یانگلنگ میں 25 اکتوبر سے شروع ہوگا اور 29 اکتوبر تک جاری رہے گا۔ اس میلے کا موضوع نئی پیداوار کی قوتوں کے ساتھ

2024 Business School Applications Skyrocket amidst Economic Uncertainty

GMAC’s annual survey shows demand growth is five times greater than the pandemic boom RESTON, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) — Across the globe, total applications to graduate business school programs in 2024 increased an impressive 12 percent from 2023 to 2024. This is a sharp reversal from the

31st China Yangling Agri High-Tech Fair to open on Oct. 25

YANGLING, China, Oct. 22, 2024 /Xinhua-AsiaNet/– The 31st China Yangling Agri High-Tech Fair will kick off in the agricultural sci-tech hub Yangling City in west China’s Shaanxi Province on October 25 and last until October 29, with the theme centering on a new future of agriculture with new quality productive

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are